EU: Pivotal Moment For Roche’s Faster-To-Apply Breast Cancer Combo
Patients preferred subcutaneous injection compared to standard intravenous administration
The European Medicines Agency is this week deciding whether or not to recommend pan-EU marketing approval for Roche’s subcutaneously injected fixed-dose combination of Perjeta and Herceptin. The agency is also deciding on a marketing application for the company's flu antiviral, baloxavir marboxil.
